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Abstract
The  interaction  between  the  patient  and  the  ECMO  (extracorporeal  membrane
oxygenation) circuit initiates a significant coagulation and inflammatory response due
to  the  large  surface  area  of  foreign material  contained within the  circuit.  This  re‐
sponse  can  be  blunted  with  the  appropriate  mix  of  biocompatible  materials  and
anticoagulation  therapy.  The  use  of  anticoagulants,  in  turn,  requires  appropriate
laboratory testing to determine whether the patient is appropriately anticoagulated.
Physicians must balance the risks of bleeding with the risks of thrombosis; the proper
interpretation of these tests is often shrouded in mystery. It is the purpose of this chapter
to help demystify the coagulation system, anticoagulants, biocompatible surfaces, and
coagulation testing so that ECMO practitioners can make informed decisions about their
patients and to spur coordinated efforts for future research to improve our understand‐
ing of these complex processes.
Keywords: anticoagulation, coagulation testing, surface coatings, ACT, aPTT, TEG,
heparin, direct thrombin inhibitors
1. Introduction
The ECMO circuit, as a whole, represents one of the largest surface areas and volumes for
blood contact in any medical device. The oxygenator surface area ranges from 0.8–2.5m2 with
a volume of 75–250 mL depending on the manufacturer and size (pediatric to adult).  In
addition, there typically is an associated 250–500 cm of polyvinyl chloride (PVC) tubing to
connect the pumps, oxygenators, and equipment to the patient, which creates an additional
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0.05–0.15 m2 surface area and 70–250 mL volume depending on length and diameter of the
tubing. When blood comes into contact with any foreign surface, a series of reactions begin to
occur  within  milliseconds  that  impact  the  coagulation  and  inflammatory  systems,  and
essentially lead to the rejection of the material by the host organism. Therefore, in order to
utilize ECMO in a clinical setting, these processes are required to be modulated through
systemic anticoagulation or the utilization of materials and coatings designed to disguise the
materials  from the body.  This  currently represents  one of  the greatest  challenges to  the
utilization of ECMO in patients, particularly in the long-term application for lung recovery
and/or lung transplantation. According to the Extracorporeal Life Support (ELSO) registry,
which is a self-reported database of ECMO patients and their associated diagnoses, equip‐
ment utilized, outcomes and complications, there are approximately 0.5 thrombotic events
and 0.5 bleeding events per patient run [1]. Although survival statistics for ECMO patients are
population-specific, the occurrence of these two adverse events often results in a 20–30%
reduction in overall survival. Therefore, it is of utmost importance that ECMO practitioners
create a better understanding of the complex processes involved in an effort to better utilize
current technology. Further, it is of even greater importance that device manufacturers and
researchers continue to work on new drugs, materials, and surfaces in an effort to modulate
activation of coagulation and inflammation. The purpose of this chapter will be to provide an
overview of the processes and principles of coagulation and anticoagulation in the setting of
ECMO as a necessary foundation for understanding this problem.
2. Cell-based model of coagulation
Since 2001, the way that coagulation has been understood has undergone some fundamental
changes. The traditional coagulation cascade has been replaced with the cell-based model of
coagulation [2]. In this model, there are essentially three phases to the clotting cascade:
initiation, propagation, and amplification. In each of the three phases, the impact of tissue
factor (TF) bearing cells and platelets has been placed at the forefront and these are the
platforms upon which much of the conversion of coagulation factors from their inactive to
active forms occurs. The cell-based model provides a more accurate picture of the way that an
enzymatic cascade works and allows for a clearer picture of the cross-talk between the
inflammatory and coagulation systems which must be appreciated by clinicians for a true
understanding of the hemostatic picture in ECMO patients. While the details of the cell-based
model are beyond the scope of this chapter, an overview of the model along with the drugs
that interact with the coagulation proteins is provided for visual reference (Figure 1)
3. Surface activation
The primary concern for most clinicians in ECMO is the prevention of thrombus formation on
the surface of the ECMO circuit. Thrombi are composed of platelets, red cells, and fibrin meshes
that are adherent to the surface. It is important to understand that cells cannot adhere directly
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to polymers, but rather require a receptor binding to a protein coating on the surface. Therefore,
the first step in the coagulation and inflammatory response to the ECMO circuit is the
adsorption (covalent or ionic reactions) of plasma proteins. This adsorption is based on
stochastic processes driven by the thermodynamic reaction kinetics between the surface
chemistry of the foreign material and the concentration of proteins available in the plasma [4].
For the ECMO circuit, these surfaces typically include PVC, silicone, polycarbonate, polyme‐
thylpentene, and/or polypropylene. Each of these materials is hydrophobic, with some being
more hydrophobic than others depending on the side chain composition of the main polymer.
The adsorptive process is also dynamic where proteins continually compete, adsorb, and
desorb from the surface depending on both time and the changing concentrations of plasma
[5]. Another important feature of this adsorptive process is that it often leads to a conforma‐
tional change in the natural 3-D protein structure (Figure 2). In simple terms, the proteins may
alter their shape to place their hydrophobic components near the hydrophobic polymer surface
so as to exclude the water along a favourable thermodynamic gradient. This change in 3-D
Figure 1. In the cell-based model of coagulation, three phases of coagulation take place on the surface of cellular ele‐
ments of the blood. While platelets take center stage, the impact of TF-bearing cells cannot be overlooked because mul‐
tiple cell types can express TF, including endothelial cells, monocytes, and macrophages. Inactive forms of the
coagulation factors are presented in blue ovals while activated versions are presented in red ovals. Coagulation com‐
plexes are enclosed in parallelograms or hexagons. Drugs that interact with the coagulation cascade are identified and
point to the specific factors they inhibit. Image adapted from Ahrens et al. [3].
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structure can subsequently expose other hidden areas of the proteins to the aqueous environ‐
ment and lead to hydrolysis (the breaking of bonds due to reaction with water) or provide
ligands for receptors on the cellular elements (platelets and leukocytes) that will enable
adhesions and subsequent cellular activation. The primary proteins of interest to prevent
adsorption include fibrinogen and complement protein C3. Adsorption of fibrinogen is
associated with platelet consumption [6]. C3 adsorption and subsequent autohydrolysis
initiates the alternative complement system leads to the production of C5, which has been
shown to significantly influence the homing of leukocytes to the intestine and lung tissues and
promote the systemic inflammatory response syndrome and its deleterious effects [7].
Coagulation and inflammatory systems are interrelated such that activation of one will often
result in cross-over activation of the other. Thus, it should be evident that the first step in
mitigation of the deleterious effects of ECMO should be on the creation of biologically inert
surfaces or masking of the surfaces from the coagulation and inflammatory proteins within
the plasma. However, despite over 50 years of research, a perfectly biocompatible surface has
not yet been created.
Figure 2. Representative image of the conformational change made by a protein in contact with a hydrophobic surface.
The red zones are hydrophobic and are hidden from the surrounding aqueous solution until the protein comes near
the hydrophobic surface. Upon approach, the thermodynamics favors a conformational change to exclude the water
molecules and allow the hydrophobic patches to contact the hydrophobic surface, thereby inducing a conformation
change that uncovers an active area of the protein (cross-hatched area). This area can react with the aqueous medium
to initiate autohydrolysis and create the active forms of compliment or coagulation proteins (through intermediate
steps such as bradykinins) or can provide the signal to activate platelets.
4. Surface coatings
In an effort to control the adsorption of plasma proteins to the ECMO circuit, the concept of
pre-coating or surface modification has been in existence since nearly the beginning of
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extracorporeal circuit utilization. This section will examine the various coating technologies
and their application to extracorporeal Technology. A table outlining the key points of each of
the coatings discussed is provided (Table 1). One overarching theme from the research studies
involving these and other novel coatings is that the strongest evidence for their implementation
comes from in vitro short-term blood studies, and nearly all clinical studies have been
performed in cardiopulmonary bypass settings. The clinical evidence for efficacy or changes
in patient outcomes is often conflicting and most clinical studies have Class IIb recommenda‐
tions to support them, and blinded, randomized trials are almost impossible to perform [8].
However, there is no evidence that coated circuits do any harm and their utility may be in
those unusual clinical cases where protocol deviation is necessary or other factors that are not
controlled may be influenced. These clinical scenarios are rare, thus creating challenges for
adequate sample size in studies including only these unusual patients.
Manufacturer Coating name Coating technology 
Medtronic Carmeda Covalently bonded heparin (anticoagulant)
Trilium Covalently bonded heparin (anticoagulant), sulfate and sulfonate groups (negative
charge), polyethylene oxide (hydrophillic)
Maquet Bioline Covalently bonded recombinant human albumin (passivation) and heparin
(anticoagulant)
Safeline Covalently bonded synthetic albumin (passivation)
Softline Amphyphilic polymer coating (reduced surface tension)
Terumo X-Coating Poly 2-methoxylacrylate (reduced cellular and protein adhesion)
Sorin Smart-X Tribloc Copolymer (Polycaprolactone-Polydimethylsiloxane-Polycaprolactone)
integrated into plastic (reduced cellular and protein adhesion)
P.h.i.s.i.o. Phosphorylcholine (reduced cellular and protein adhesion)
Table 1. Listing of manufacturers and their coating products.
4.1. Albumin
One of the first proteins to be used for pre-coating blood-contacting surfaces was albumin [9].
Prior to the introduction of ionic or covalently bound surfaces, albumin was added to the circuit
prime of adult circuits to increase the oncotic pressure of the priming solutions. In pediatrics,
it was often used as a precursor to the addition of packed red cells. The purpose of the albumin
pre-coat was to provide a base layer of protein that would delay or mitigate the biological
response to the heavily hydrophobic surfaces [9, 10]. Adsorbed albumin both increases the
hydrophilicity of the surface and provides a competitive protein that the fibrinogen must
displace. Albumin covalently linked to surfaces (e.g., Safeline® by Maquet) ensures its
retention and prevents displacement. Research on this coating technique has demonstrated
short-term reductions in the concentration of fibrinogen and platelets on the surface and some
evidence that it reduces complement activation [11].
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4.2. Heparin
The most widely used anticoagulant in cardiopulmonary bypass and ECMO has been
unfractionated heparin (UFH). The use of UFH has contributed significantly to the advance‐
ment of cardiac surgery and improved outcomes in these patients and will be discussed in
detail in subsequent sections. Because UFH was such a successful systemic anticoagulant, a
natural extension would be to immobilize it to a blood-contacting surface to provide local
anticoagulant effects and potentially decrease some of the side effects of systemic anticoagu‐
lation, particularly in post-operative cardiac surgery patients where surgeons desire blood
coagulation at the site of the incision but not in the extracorporeal circuit. Immobilization can
be accomplished through covalent linkage to the surface, polymerization on the surface, or
ionic interactions with the surface.
End-point covalent linkage of heparin to polymer surfaces was first made commercially
available as Carmeda Bioactive SurfaceTM (Carmeda, Switzerland), available on Medtronic
tubing and oxygenators. The process for linkage is relatively straightforward and applicable
to a variety of biological compounds. The process begins adding a layer of an amide (NH3)
containing material to the surface. This amide surface is then easily reacted with the end of the
polysaccharide chain of heparin. The covalent linkage of heparin has been demonstrated to be
reproducible and stable, with the heparin reactivity present several hours after the initial
exposure to the blood [12]. Other manufacturers have made similar heparin coatings (e.g.,
Rheoparin (Medos) and Bioline (Maquet)) using composite covalent and/or cross-linking
techniques. The largest challenge with these methods is that the active site of heparin may be
involved in the binding area and thus not available for interaction with antithrombin. In
addition to covalent linkage, ionic linkage has also been demonstrated, most notably in the
Duraflo (Baxter) products. However, the difference between ionic and covalent linkage is the
retention of the heparin molecule after blood contact in the covalent bonding versus leaching
of the heparin in the ionic linkage [13, 14].
Overall, the use of a heparin coating has been seen as a success in the medical community, and
nearly 300 papers on heparin-coated circuits have been published. Most in vitro or animal
models demonstrate benefits of heparin coating including reduced soluble thrombin produc‐
tion, platelet binding, and D-dimer production [12, 15–19, 20]. With respect to inflammation,
most studies demonstrate reduced inflammatory response, particularly in the interleukins,
alternative complement pathway and polymorphonuclear cells, compared to controls and
other coating systems [12, 20–25, 26]. Meta-analyses of the benefits of heparin coating have
consistently found improvements in transfusion requirements, arrhythmias, ventilator times,
and lengths of stay in the hospital or ICUs when using heparin-coated circuits for cardiopul‐
monary bypass [17, 27, 28, 29]. One important aspect of many of these studies has been that
many have focused on short-term impacts of heparin coatings. These studies also indicate that
it does no harm to the patient, and therefore it may be worthwhile to utilize this technology
in the absence of large studies containing a heterogeneous patient cohort. However, some
studies have been published that demonstrate no appreciable systemic benefits to heparin
coating during cardiopulmonary bypass [30] or for ECMO beyond 6 hours, for reasons that
have never truly been elucidated [19]. Practitioners are cautioned to interpret these studies
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carefully because of their short-term nature and the significant effects of the air-blood interface
found during cardiopulmonary bypass (CPB). In a statement which is reflected in the antico‐
agulation guidelines from the Extracorporeal Life Support Organization, “ECMO patients are
highly complex and the additional time on support cannot be ignored as a key factor in their
outcomes” [31].
4.3. Polymer surfaces
In addition to the biologic molecules of heparin and albumin, there are several other surfaces
that have been developed with the aim of increasing hydrophilicity or surface charge similar
to that of the endothelial cells lining mammalian blood vessels. These are typically polymers
including phosphorylcholine, poly 2-methoxyethylacrylate, polyethylene oxide, and triblock
surface-modifying additives. Each will be discussed in terms of relative chemistry, and studies
examining their effectiveness at blunting the coagulation and/or inflammatory response.
4.3.1. Phosphorylcholine (PC)
Phospholipids make up the bulk of the cell membrane in mammalian cells and provide the
ability to separate the plasma and cytosolic solutions, both of which are aqueous environments.
Phosphorylcholine (PC) is a zwitterionic phospholipid compound with no overall charge that
is found on the plasma leaflet of the red cell membrane. This compound has been previously
demonstrated to be non-thrombogenic, as opposed to its cytoplasmic counterpart, phospha‐
tidylserine, which has been shown to be pro-thrombogenic [32]. It has been successfully used
in stent coating technology, and has also been used to coat PVC and polypropylene and
polymethylpentene oxygenators for cardiopulmonary bypass and ECMO uses under the
brand name P.h.i.s.i.o. from Sorin. The effects of PC on PVC have been shown to reduce
fibrinogen binding and subsequent platelet binding through GPIIb receptors [32]. PC-coated
circuits perform similar to heparin-coated circuits [33] in clinical studies with evidence of
improved platelet retention and reduced postoperative transfusion requirements, but no
effects on overall outcomes [34]. Further, PC coating may increase immune cell (T-Cell)
response through an IL-8 mechanism [35].
4.3.2. Polyethylene oxide (PEO)
Polyethylene oxide (PEO) is a water-soluble, non-toxic, and non-immunogenic polymer that
has been shown to reduce protein and bacterial adhesion in a variety of surfaces [36]. Its utility
in blood-contacting materials was originally designed for increasing the hydrophilicity of the
silicone polymers that made up the early membrane oxygenators. Silicone, while relatively
biocompatible and an ideal biomaterial for many applications, is very hydrophobic, and
increased hydrophobicity leads to increased protein adhesion, particularly fibrinogen adsorp‐
tion [37]. A challenge with silicone coating is that production of functional groups for attach‐
ment is not as easy as with other polymers. However, it is possible with the use of mercury
lamps to create radicals and oxidation by O2 plasmas to create alcohol groups. Alternative
preparations begin with incorporating hydromethylsilicone in the polymerization process and
the subsequent use of platinum catalysts can create the functional groups for coating attach‐
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ment. Coating of PEO to the surface of silicone rubber has been demonstrated to increase water
contact angles (increased hydrophilicity) and reduce both fibrinogen and albumin adhesion
by 90% [36]. These reductions are dependent on a number of factors, including the molecular
weight of the PEO and the functional structure of the PEO (single, monofunctional chains or
bi-functional, loop structured PEO). Like most coating technologies, this coating is not a pure
monolayer and gaps do exist. The use of PEO is commercially available as part of the Trillium
package on Medtronic tubing. Studies using the Trillium surface have shown reductions in
inflammatory markers and reduced bleeding events [38–40], but also increased stroke rates
[38] from cardiopulmonary bypass. Like most CPB studies, these are small, single-center
studies with variable sample collection, and no long-term studies have been performed.
4.3.3. Poly 2-methoxyethylacrylate
Poly 2-methoxyethylacrylate (PMEA) is a polymer coating generated on polypropylene and
PVC surfaces through plasma charge preparation of a surface. Allowing 2-methoxyacrylate to
react with the surface provides a weakly hydrophilic surface that has improved biocompati‐
bility characteristics. PMEA was originally developed for plasma separation devices to permit
non-hemolytic dry priming of the devices [41]. However, it was soon realized that this coating
provided significant reduction in platelet and leukocyte activation and adhesion, and coagu‐
lation and complement activation [42]. Numerous laboratory studies have been undertaken
to understand why this particular polymer has such effects, including variations of the polymer
to include hydroxyl, phenyl, ethyl, and other groups. In all cases, the PMEA adsorbed fewer
proteins and the protein conformation changes differed very little from the native surface [42,
43]. This coating is currently marketed under the SMARTx brand from Sorin. Clinical and in
vitro studies using cardiopulmonary bypass circuits with this coating technology (available
as the X Coating from Terumo) have had mixed results. Like other coatings, PMEA-coated
systems have improved markers of inflammation and some clinical outcomes over non-coated
systems [44, 45]. However, several studies have demonstrated increases in ventilator times,
chest tube output, and inflammatory markers of PMEA compared to other coatings [39, 46,
47], while others studies found little or no difference between PMEA and heparin-coated
surfaces [44, 48].
4.3.4. Surface-modifying additives
Another technique for producing more biocompatible surfaces is the use of surface-modifying
additives (SMAs) that can either be blended with the base polymer resins during manufac‐
turing and subsequently rise to the surface, or they can be coated onto a device’s blood-
contacting surfaces. One such SMA, a polycaprolactone-polysiloxane-polycaprolactone
triblock copolymer, has been incorporated into the polyvinylchloride base resin and coated
onto a polypropylene membrane [49]. The incorporation into the bulk resin yields significant
surface modification and in initial in vitro tests demonstrated large reductions in thrombin
and complement generation on SMA surfaces compared to uncoated surfaces. Clinical studies
of the SMA coating have provided some evidence for a change in physiologic response,
typically increased blood pressure and anti-inflammatory IL-10, reduced platelet and blood
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loss [50–52], and reduced use of inotropes [50, 51, 52]. Interestingly, terminal complement
complex and complement protein C3 have been found to be no different in the SMA and control
(uncoated) circuits in several studies [50, 53], and there is no difference in the generation of
high-intensity transient signals in transcranial Doppler between SMA and non-coated circuits
[52].
5. Anticoagulants
The need for systemic anticoagulation has been understood since the earliest extracorporeal
circuits were developed in the laboratories in the 1800s. It wasn’t until the discovery of the
heparin molecule in the early 1900s that safe anticoagulation could be achieved for the
purposes of moving and storage of blood outside of the body. As a result, heparin is the most
widely used anticoagulant for ECLS owing to its long history, cheap production costs and
reversibility with the fish-based enzyme, protamine. In addition to heparin, there are other
classes of anticoagulants, including direct thrombin inhibitors. These have been utilized in
extracorporeal circuits, particularly when heparin is not recommended to be used, such as
patients with a heparin allergy (i.e., heparin-induced thrombocytopenia) or protamine allergy.
Each of the anticoagulants will be discussed in terms of their mechanisms of action, cofactors
required, dosing for ECMO, and case studies or clinical trials related to their use in ECMO.
Table 2 at the end of this section provides relevant dosing for pediatric and adult patients
along with responses to bleeding for each drug.
5.1. Heparins
Heparin is a natural anticoagulant produced by the basal and mast cells in the body. Its
discovery in 1916 was instrumental in the progress of blood-contacting devices because it could
effectively halt the coagulation process which was a consistent problem for blood-contacting
materials at the time. Heparin is a variable length carbohydrate in the glycosaminoglycan
family, with molecular weights ranging from 3 to 30kDa. The primary mechanism of action of
heparin is its ability to interact with another naturally occurring anticoagulant, antithrombin
(AT, discussed below) and increase its ability to bind and inhibit the enzymatic activity of
thrombin (Factor IIa) and Factor Xa by over 2,000-fold [54]. Only heparins containing 15 or
more saccharide chains are capable of binding and inhibiting thrombin and FXa; heparins with
5–15 saccharide chains can only bind and inhibit FXa. Of note, the heparin/AT complex can
only bind to soluble thrombin or FXa due to the large size of the AT molecule. Thrombin or
FXa already complexed within an adherent clot cannot be affected by the presence of heparin
and will continue their enzymatic processes unimpeded.
Pharmaceutical preparation of heparin is derived from the mucosal tissues of farm animals
including pigs and cows, although most current preparations are derived from pigs due an
increased incidence of heparin-induced thrombocytopenia (HIT) with bovine-derived heparin
[55]. As such, the derivation of heparin from these tissues is unfractionated, containing all the
molecular weights. Low molecular weight heparin can be derived through a size fractionation
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or chemo-enzymatic process. Heparin can be given intravenously or subcutaneously, and has
a relatively short half-life of 60–90 minutes (unfractionated) to 4–5 hours (low molecular
weight) [56]. As such, unfractionated heparin (UFH) is typically administered continuously
intravenously while low molecular weight heparin (LMWH) is administered once or twice
daily subcutaneously.
Drug  Clearance  Dose (mg/kg/hr) Monitoring Bleeding
Child  Adult  Child  Adult  Child & Adult 
UFH Renal 15–28 IU/kg/hr 10–18 IU/kg/hr aPTT 1.5–2X
(<100 sec)
ACT 180–220
sec
Anti-Xa 0.3-0.6
IU/mL
PTT 40–60
ACT 180–
220 sec
Protamine
1.5 mg/100
IU UFH
(reversal)
LMWH Renal 1.2 subcutaneous
q 12hrs
1mg/kg
subcutaneous
q 12hrs
Anti-Xa 0.5–1 IU/mL Protamine
1.5 mg/100
IU LMWH
(partial
reversal)
Argatroban Hepatic Infusion: 0.045
Adjust 0.06–0.015
Hepatic compromise
0.012
In HIT: 0.006-0.6;
Infusion: 0.12
In HIT: 0.012
PTT 1.5–3X
(<100 sec)
ACT 160–200
PTT 40–120
ACT 170–
200
FVIIa**
30–90
μg/kg
Bivalirudin Proteolysis:
75%
Renal:
25%
Bolus 0.125–0.25
Infusion
Primary: 0.125–0.2
Tx UFH: 0.1–0.8
Infusion:0.08–0.2
Adjust 0.03
PTT 50-70
ACT160–200
PTT 40–120
ACT 200–
220
Aspirin Liver 1–5 mg/kg/d
Max 91 mg
TEG MA and α depression
TEG AA Inhibition 70%
Platelet
Transfusion
Clopidogrel Liver 0.2 mg/kg/d 1 mg/kg/d TEG MA and α depression Platelet
Transfusion
Dypyridamole Liver 1.5 mg/kg/d TEG MA and α depression
TEG ADP net G 4–8
Platelet
Transfusion
Note: **Based on <10 case reports.
Table 2. Dosing guides for anticoagulants for mechanical circulatory support.
Heparin is cleared through two mechanisms. Low doses of heparin are rapidly cleared through
a reticuloendothelial process, whereas higher doses which saturate these processes are cleared
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through the kidneys in a much slower fashion [57]. Additionally, heparin effects can be rapidly
reversed through administration of a reversal agent, protamine sulfate, which is negatively
charged and binds with UFH or LMWH to form a stable ionic pair preventing binding to AT3.
The ionic complex goes on to be broken down through the reticuloendothelial system.
The ease of production, rapid onset, relatively linear dosing and ease of reversal has made
heparin the standard anticoagulant for cardiopulmonary bypass and subsequently ECMO for
the past 50+ years. For cardiopulmonary bypass, a loading dose of 300–350 units/kg is
administered, which results in an activated clotting time >400 seconds (see ACT below), and
the standard perfusion target of ACT>400 sec for the duration of surgery is easily met with
additional bolus dosing as necessary. For ECMO, loading doses of 30–100 units/kg have been
used for initiation and then a continuous infusion between 10 and 30units/kg/hr is adminis‐
tered according to a specified coagulation test target protocol [58].
5.1.1. Heparin-induced thrombocytopenia
In addition to binding to AT to mediate its anticoagulant effect, heparin can also interact with
platelet factor 4 (PF4) to form very large (>670kDa), stable complexes. These complexes are
more common with UFH than LMWH and can trigger pre-existing PF4/heparin-intolerant B
cells [59]. The chances of a B cell reaction leading to proliferation and antibody production
may increase in some patients with repeated exposure to exogenous UFH, leading to a
condition called heparin-induced thrombocytopenia (HIT). HIT is characterized by a sudden
and severe drop in platelet count, diffuse thromboses resulting in petechiae, and subsequent
increases in risk for stroke, pulmonary embolism, or myocardial infarction. HIT occurs in
approximately 2.5% of the general population, with higher incidences in patients with repeated
heparin exposure. HIT is formally diagnosed through either an immunoassay to identify
antibodies against the heparin-platelet factor 4 complex or the gold standard functional assays
that measure the platelet activating capacity of this complex [55]. Patients who are found to
be HIT positive can no longer receive heparin without serious risk for stroke or sudden death.
Alternative anticoagulants are typically used (see direct thrombin inhibitors below). High dose
IV gamma globulins or plasmapheresis can also be employed to reduce the presence of the
heparin antibodies and mitigate the effects of HIT [60, 61].
5.1.2. Antithrombin
Antithrombin (AT) is a 58 kDa serine protease inhibitor produced by the liver. Because a
majority of the coagulation cascade proteins are themselves serine proteases, AT can target
many of them; including kallikrein, plasmin, FXIIa, FXIa, FXa, FIXa, FVIIa, and FIIa. In the
presence of heparin, AT activity against FIIa, FIXa, and Fxa is increased. AT inhibition of FIIa
is accelerated 2,000–4,000, and only 500–1,000-fold against FXa [62]. With sufficient calcium
and heparin, AT inhibition of FIXa can increase over 1 million fold [63].
In patients on heparin therapy with no known genetic deficiency in AT production, the
apparent heparin resistance (i.e., increasing heparin dosing with no effect) can often be
attributed to low AT levels in the plasma. AT levels also change developmentally, with
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approximately half as much AT at birth that rises towards adult levels around 6 months of age
[64]. The drop in AT levels can occur for a variety of reasons in the setting of ECMO. First and
foremost, for pediatric patients, there is a high likelihood of factor dilution when connecting
to the ECMO circuit (average ECMO circuits range from 270 −700 mL and are primed with
packed red cells and/or crystalloid). Second, the activation of the coagulation cascade as a result
of the additional foreign surface, inflammatory response to the hypoxic state, and the surgical
procedure can cause significant amounts of AT to complex with the activated blood elements
in equimolar and extremely stable complexes [65] as well as to complex with any immobilized
heparin on the surface of the ECMO circuit [66].
Administration of AT on ECMO is routinely performed, and there are reports of patients who
have received only AT as their sole anticoagulant [58]. There are relatively few studies that
have examined the effects of AT administration on ECMO patients. Most are severely under‐
powered, lacking sufficient events for efficacy analysis. However, those that are published do
indicate that AT increases heparin levels in the blood and reduces the heparin dose in ECMO
patients, and that AT can be safely administered to patients on ECMO without increased risk
of bleeding [67–69, 70]. There have been reports of increased failure rates of ECMO circuits in
patients receiving AT, but this may be due primarily to sub-therapeutic heparin effect (for
which AT is being given) [68]. However, it is the lack of true efficacy (reduced bleeding or
thrombosis events) in these studies that continues to raise questions about the utility of this
costly therapy in ECMO patients.
5.2. Direct thrombin inhibitors
In the setting of conditions that limit the use of heparin, such as HIT, direct thrombin inhibitors
(DTIs) can be used. These drugs specifically target FIIa and have the advantage that they do
not require cofactors like AT to function; nor are they neutralized by PF4 like heparin [71].
Furthermore, they are small molecules and can bind to FIIa that is currently enmeshed in a
clot as well as FIIa in the plasma (i.e., soluble and insoluble thrombin). The primary disad‐
vantage to their use in ECMO is the relative lack of experience using these drugs along with
the differing clearance mechanisms that may make one DTI preferable to another in the setting
of multiple organ failure. There is also no antidote, unlike heparin which can be specifically
reversed with protamine. Each of the various DTIs that have been used with ECMO will be
discussed, along with specific mechanisms of action and dosing that have been documented
in ECMO patients.
5.2.1. Argatroban
Argatroban is a small site-directed DTI first discovered in 1981 and became the first oral DTI
available in the market for patients with HIT. The primary interaction is a reversible binding
between a hydrophobic portion of the argatroban molecule and the hydrophobic pockets near
the active site of the thrombin molecule [72]. Although primarily given intravenously, the main
advantage that argatroban has over other DTIs like Bivalirudin is that it is a very small molecule
(∼500 Da). The half-life of argatroban is ∼50 minutes, and it is cleared solely through hepatic
mechanisms, making it suitable for use in patients with acute renal failure. Anticoagulation
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monitoring is typically performed through the activated thromboplastin time (aPTT) test
because argatroban can lead to false increases in the international normalised ratio (INR) level
[71].
Of all the DTIs, argatroban has seen the greatest clinical use in the settings of cardiopulmonary
bypass and ECMO for patients with confirmed or suspected HIT [71, 73, 74]. Dosing for
argatroban in these therapies ranges from 0.1–250 μg/kg loading dose depending on the setting
(CPB vs PCI), patient age (neonates may require a smaller bolus because their thrombin
generation is lower than adults [75]), and physician experience, or 10–30 μg in an extracor‐
poreal circuit. The loading dose is followed by 0.1–24 μg/kg/min continuous infusion [71, 74].
Target aPTTs are typically 1.5–2 times baseline or 45–65 seconds [71] or activated clotting times
(ACTs) of 250–300 seconds [74]. Patients receiving argatroban during ECMO have experienced
similar thrombotic complications as those on traditional heparin therapy (including circuit
thrombosis, disseminated intravascular coagulation, and diffuse thrombotic disease) [71].
Although the case series are small, rates of complications hover around 25%, which is lower
than the combined bleeding and thrombotic complications reported by ELSO for their registry
(∼40–50%). Larger, randomized control studies should be performed to determine whether
the use of argatroban is associated with significantly reduced complications in the extracor‐
poreal setting or if these small case series are simply a result of higher anticoagulation vigilance
in the setting of a higher risk patient.
5.2.2. Bivalirudin
Bivalirudin is a synthetic version of the leech-derived anticoagulant hirudin. It is a slightly
larger molecule than argatroban (∼2,000 Da) requiring that it be delivered intravenously.
Bivalirudin has two thrombin binding sites, one in the catalytic pocket of thrombin and the
other on fibrin-binding exosite. After binding to thrombin, a portion is cleaved off that will
restore some thrombin activity. The remainder of the drug is cleared through renal mecha‐
nisms, making it suitable for use in patients with acute liver dysfunction where argatroban
may be unsuitable [72]. Because of the partial enzymatic cleavage, the half-life of bivalirudin
is shorter (∼30 min), which makes it attractive for short-term procedures like percutaneous
coronary intervention and cardiopulmonary bypass [71]. However, the challenge with using
bivalirudin is that the drug is degraded with stasis of blood flow and therefore may cause
unexpected clotting in the reservoir of the cardiopulmonary bypass machine or in any area of
stasis in the ECMO circuit. Recommendations have been made by experts that left heart volume
should be reduced as much as possible to prevent the occurrence of a “cardiac reservoir” and
possible thrombosis [76]. For other extracorporeal therapies where there is no reservoir (ECMO
or VADs), bivalirudin may be preferable over argatroban for patients who are in liver failure.
Dosing for bivalirudin has been reported at 0.15–0.5 mg/kg bolus followed by 0.12–0.25
mg/kg/hr. The target ACTs and aPTTs are similar to that of argatroban at >200 seconds and
1.5–2 times baseline, respectively [71].
In the setting of ECMO, small case reports and single-center retrospective reviews have been
generated describing the use of bivalirudin over heparin [77–79, 80]. One such report from
Ranucci et al. [80] described the reduced use of platelet and plasma donor products in patients
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receiving bivalirudin for postcardiotomy ECMO compared to patients receiving UFH. Another
small case-controlled study from Pieri et al. [81] demonstrated less variation in aPTT but no
difference in bleeding and thrombotic complications versus UFH. The consensus from these
reports has primarily been that bivalirudin use in the extracorporeal setting is feasible
provided the patients are closely monitored.
5.3. Factor Xa inhibitors
Another alternative to heparins is to use Factor Xa Inhibitors, which can either bind directly
to FXa to prevent interaction or can catalyze inhibitory reactions via AT3 (similar to the action
of UFH). The primary advantage to these drugs is that they can inhibit free and platelet-bound
FXa and can be dosed infrequently due to long half-lives, and can be administered with
intermittent subcutaneous injections. Several oral FXa inhibitors have been approved by the
FDA for treatment of venous thromboembolism (VTE) and atrial fibrillation (AF). These
Figure 3. Regulatory pathways of platelets including their stimuli and pharmacologic inhibitors. Reprinted with per‐
mission from Macmillian Publishers Lt: Nature Reviews Drug Discovery, Copyright 2003 [85].
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include rivaroxaban, dabigatran, edoxiban, and apixaban. Dosing is typically once per day,
and monitoring is performed performed through an anti-FXa assay or through aPTT [82].
There are no data currently on the use of these agents in the acute care setting, but it may
become a possible choice for patients on long-term ECMO who are extubated and awaiting
lung transplantation. A major caveat for this drug is that it has no antidote and in the case of
worsening renal function, the drug will not be cleared efficiently and dialysis does not appear
to alter plasma levels [83]. However, a recent study on a double-blind placebo trial of a general
FXa-antidote (andexanet) is promising [84].
5.4. Anti-platelet agents
Platelet activation and deposition occur rapidly in the setting of extracorporeal circulation and
have been a primary focus of coating technologies developed for extracorporeal therapies (see
above). The deposition of fibrinogen to the artificial surfaces provides ample binding and
activation signals to the platelet through their GIIb/IIIa receptors [85, 86]. Further, the altered
shear stress environments are also known to activate platelets [87, 88] to form aggregates with
other cells, including monocytes and other platelets via von Willebrand factor (vWF) and p-
selectin mechanisms under inflammatory conditions related to mechanical circulatory support
devices [89, 90]. Pharmacologic intervention into platelet activation and adhesion has only
been recently explored in the laboratory and a few small case studies, but most studies show
a potentially beneficial effect. Anti-platelet agents (Figure 3) have a long history in other forms
of mechanical circulatory support such as the implantable ventricular assist devices [91–93],
stents [94], and mechanical heart valves [95]. Anti-platelet therapy incorporation into ECMO
anti-coagulation treatment has been successfully applied in La Pitie Hospital and reported
previously [96, 97].
5.4.1. Nitric oxide
Nitric oxide (NO) is a natural inhibitor of platelet activity through cGMP mechanisms similar
to those of dipyridamole [85]. Recently, efforts have begun to be explored in the laboratory to
incorporate NO-releasing polymers in the ECMO circuit [98] and to provide NO in the sweep
gas [99, 100, 101]. The reasoning for its use in the setting of extracorporeal life support is that
the half-life is so short (2–6 sec) that only a local effect occurs [102]. This is the goal of the coated
circuits where the anticoagulation activity is sequestered to the artificial surfaces and does not
act systemically. In vitro and animal studies of the use of NO on ECMO circuits have demon‐
strated a significant improvement in platelet functionality and retention of platelets with
minimal generation of the undesirable side effects of nitric oxide infusion, specifically
methemoglobin [100, 101, 102]. The primary downsides to this type of therapy are the lack of
current devices, which can accurately dose nitric oxide through the membrane, and the high
cost of nitric oxide therapy. Materials that release nitric oxide have a finite lifespan (several
hours up to 1 week) and regeneration of the NO production has yet to be realized. Future
developments as companies and other research enter this space may provide unique solutions
to these problems, making NO a viable adjunct to the anticoagulation regimen.
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5.4.2. Clopidogrel
Clopidogrel is a specific inhibitor of ADP receptors on platelets that is often used as part of
dual antiplatelet therapies in patients undergoing percutaneous coronary intervention (PCI)
for stent placement or balloon angioplasty. It has been used in ventricular assist device patients
in an effort to reduce pump thrombosis [103, 104]. Small subsets of patients receiving clopi‐
dogrel in addition to other anticoagulants while on ECMO have also been reported [105, 106].
Outcomes from patients receiving clopidogrel on mechanical circulatory support devices are
similar to those receiving traditional anticoagulants alone. Transfusion requirements tend to
be increased, with slightly more units of red cells and/or FFP required, but no ultimate effect
on outcome has been noted.
5.4.3. Aspirin
Aspirin (acetylsalicylic acid) is an irreversible cyclooxygenase (COX) inhibitor in platelets that
affects the COX-1 variant in a greater fashion than the COX-2 variant [107]. This effectively
blocks the production of thromboxane from the platelet, which is a potent stimulator of
surrounding platelets. Aspirin therapy has been recommended alone or as an adjunctive
therapy in a variety of cardiovascular diseases, such as the prevention of primary or secondary
myocardial infarctions and strokes [108–110], management of stents and mechanical valves
[111–113], and the prevention of embolic phenomenon on ventricular assist devices [91, 93,
103, 114, 115]. The use of aspirin on ECMO technology has been reported in some small case
series [116] and as part of the regular treatment of ECMO at La Pitie [96]. Because it is an
irreversible inhibitor, there has always been concern for bleeding events post-ECMO until new
platelets are produced by the body in the absence of aspirin. Interestingly, in contrast to the
other anti-platelet agents mentioned here, the use of aspirin has been shown to reduce the need
for transfusions [116]. In the same study, the use of aspirin was shown to dramatically reduce
platelet binding to the surfaces of oxygenators through scanning electron microscopy imaging.
Given the limited impairment of aspirin on the platelet systems (decreased thromboxane
production to limit activation) and the apparent lack of adverse events in these small studies,
and its routine use in ventricular assist devices, a multi-center trial of aspirin as adjunctive
therapy in the ECMO setting may be warranted.
5.4.4. Dipyridamole
Dipyridamole is a phosphodiesterase inhibitor that prevents the breakdown of cAMP, which
is a key component in the prevention of signal transduction in platelet activation [117]. Like
aspirin therapy, it has been extensively used in the realms of synthetic vascular graft, stent and
valve therapies [111, 118] as well as ventricular assist devices, particularly in the development
of the Berlin Heart protocols [91, 104, 114, 119]. The use of dipyridamole in the setting of ECMO
has been reported in single-center studies aimed at demonstrating safety [96]. Interestingly,
there have also been attempts at producing dipyridamole conjugated surfaces for applications
in synthetic grafts [120]. The chemistry is quite similar to what would be required for use in
ECMO devices and could be readily translated.
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5.4.5. GPIIb/IIIa inhibitors
GPIIb/IIIa inhibitors are drugs specifically targeted to the GPIIb/IIIa receptor on the surface of
platelets permitting their adhesion to fibrinogen. These types of drugs are commonly used in
the settings of percutaneous coronary interventions (PCI), but almost never used in the setting
of extracorporeal mechanical circulatory assist, particularly ECMO. There is one small case
report (N=18) on the rescue of PCI patients in cardiogenic shock using VA-ECMO [105]. The
authors reported successful outcomes for most of the patients (65%) with a small subset (5
patients) who received GPIIb/IIIa inhibitors. Compared to the other antiplatelet agents used,
those with the GPIIb/IIIa treatment had much higher transfusion requirements than those
receiving only heparin. The authors attributed this to a consumptive coagulopathy that was
set up by the use of the additional agents; although no increase in mortality was seen.
5.5. Antifibrinolytics
Cannula and surgical site bleeding are common complications in ECMO patients, particularly
in cardiac ECMO where the patient may have an open chest or undergone significant vascular
repair. According to the ELSO registry 7–21% of patients will experience one of these compli‐
cations during their ECMO run [1]. The numbers vary based on patient age and reason for
ECMO. Often this bleeding can occur in the face of reasonable anticoagulation parameters or
even when anticoagulants are withheld. The reasons for this can be attributed to one or a
combination of issues including low platelet counts, deranged hemostasis associated with
consumptive coagulopathy where the circuit may be consuming most of the patient’s coagu‐
lation factors and increasing the risk for bleeding, and fibrinolysis. Patients who are at risk for
increased bleeding (e.g., planned surgical procedures) while on ECMO have often been treated
with an antifibrinolytic drugs (e.g., aminocaproic acid or tranexemic acid) in an effort to reduce
the chances for existing clots to break down and keep surgical sites intact. Evidence from the
literature in these patients suggests that the use of antifibrinolytics decreases surgical site
bleeding, but does not impact intracranial hemorrhage [121, 122]. There is some concern that
using antifibrinolytics may decrease circuit lifespan because as thrombus is deposited on the
interior surfaces, it cannot be remodelled in a normal fashion and continues to build to the
point of requiring a component change. Some studies have found the use of antifibrinolytic
drugs increases the change-out rates of ECMO circuits by approximately three-fold, while
others have found no relationship [123]. Administration is typically done as a loading dose
(e.g., 100 mg/kg aminocaproic acid) followed by 72 hours of continuous infusion at a lower
dose (e.g., 25–30 mg/kg aminocaproic acid) [121, 122]. Additional vigilance should be provided
to the patient and ECMO circuit during a period of treatment to be aware of additional
thrombosis and address it appropriately.
6. Coagulation testing
As a consequence of the use of systemic anticoagulants, there exists a need for laboratory
testing of the blood to determine whether acceptable levels of anticoagulation have been
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reached. There have been two tests specifically developed to address the needs of coagulation
testing as a result of heparin, the Heparin Activity Assay and the Activated Clotting Time,
while others that have been in existence for the monitoring of hereditary bleeding disorders,
pro-thrombin time and activated partial thromboplastin time, have been accepted for use in
these instances. Another, relatively recent class of testing, thromboelastography or thromboe‐
lastometry, has been developed to provide a more global view of hemostasis with the purpose
of identifying specific points where deficiencies might exist and interventions could be
possible. Each of the tests will be discussed in terms of technical advantages and disadvantages
as well as application to ECMO coagulation monitoring. Table 3 at the end of this section
provides an overview of the tests discussed.
6.1. Activated clotting time (ACT)
The ACT is a point-of-care whole blood test that was developed during the early adoption of
cardiopulmonary bypass because perfusionists needed a way to rapidly determine in the OR
setting whether a sufficient dose of heparin had been given to ensure that bypass could be
conducted safely. The stimulating agents of the ACT (Celite or kaolin, silica, calcium and
phospholipid) are in high concentration and designed to elicit a strong coagulation response
and induce clot formation within 800 seconds even at high heparin concentration. Thus, the
ACT was developed as essentially a binary coagulation test in the face of heparin and its
linearity is primarily associated with higher concentrations of heparin that are seen during
cardiopulmonary bypass (350–400 IU/kg). From the mid-1970s to the mid-2000s, most ECMO
centers have used the traditional ACT as their gold standard test for determining heparin
administration. However, after 2000, another form of the ACT became available. The low-range
ACT (ACT-LR), which was designed for use in PCI settings where lower heparin dosing was
the norm (150–200 IU/kg) and where the traditional ACT was not reproducibly linear, has
become frequently used by ECMO practitioners. In fact, over 90% of hospitals use the ACT
(traditional or ACT-LR) as part of their routine coagulation testing on ECMO [58]. Further‐
more, a number of manufacturers began to alter their test procedures to reduce the size of the
machine and the amount of blood required to run the test. Some ACT machines are based on
mechanical methods of larger volumes (2mL) of blood to detect clot formation in real-time,
while others use very small volumes (100 μL) in an optical-mechanical system in accelerated
time, and still others use electrochemical resistance changes in even smaller volumes (10 μL)
in real-time to determine clot formation. Despite these differences, clinicians have traditionally
clung to relatively narrow ranges (180–220 seconds) to determine heparin doses [58]; with
different machines having ACTs which may not correlate with each other. This has created
significant confusion in the ECMO community and spurred several practitioners to look for
alternatives to this long-standing tradition of ACT-based heparin management on ECMO.
6.2. Activated partial thromboplastin time (aPTT)
The aPTT is a well-established, validated laboratory test for the monitoring of a patient’s
coagulation status that is used for all patients where bleeding is a concern, not just those on
ECMO. It is a laboratory-based test of plasma, thus eliminating the effects of platelets and other
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cellular elements from the test process, and is performed on citrated blood which removes the
cofactor calcium from the coagulation cascade during collection. This effectively arrests the
clotting cascade at the levels of factor IX and X and below, preventing further progression
through the common pathway until exogenous calcium is added. Similar to the ACT, the
initiating agent is silica, which represents blood activation by a foreign substance, or the
intrinsic pathway. However, the amounts of silica and phospholipids and the lack of other
exogenous factors make the aPTT reagents a milder pro-coagulant and particularly useful for
low-dose heparin monitoring. Recently, the aPTT has begun to find favor amongst clinicians
for monitoring heparin therapy on ECMO because it has a better correlation to the heparin
doses in adults [124–127], and is now typically measured on the modern ECMO patient [31].
The trend in lower heparin dosing and use of the aPTT have been shown to reduce patient
bleeding events, and thereby decrease mortality [126]. aPTT goals for most patients are 1.5–
2.5 times age-normal values., which is important for the neonatal patient who will have
prolonged aPTT times due to the nature of the development of their coagulation system [64, 75].
6.3. Thromboelastography
Thromboelastography (or thrombelastometry) is a real-time image of the coagulation of whole
blood in the presence of a stimulating agent (typically kaolin and calcium). Two main manu‐
facturers have abbreviated their tests as TEG and ROTEM, respectively. The advantages of this
test are that it provides several pieces of information related to different aspects of the
coagulation cascade (Figure 4), instead of just a single endpoint of “thrombus formed” that is
found in the PT/INR, ACT, and aPTT tests. Addition of the enzyme heparinase to the test
Figure 4. Overview of the TEG tracing. The initial phase of the curve (R time) represents the time from initiation to the
beginning of clot formation via the enzymatic activation of coagulation factors through thrombin. The parameters K
and α represent the clot kinetics as fibrinogen cross-links begin to form. The MA is the ultimate clot strength and is
composed of 80% platelet concentration and function plus 20% fibrinogen concentration and function. The fibrinolysis
cascade is represented by the Ly30 and EPL parameters. TEG® Hemostasis Analyzer tracing images are used by per‐
mission of Haemonetics Corporation. TEG® and Thromboelastograph® are registered trademarks of Haemonetics Cor‐
poration in the US, other countries, or both.
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sample can also give a clinician a glimpse of the patients’ underlying hemostasis independent
of the presence of heparin anticoagulation, and reveal a coagulopathy that may be masked by
the presence of being on an anticoagulant. The use of heparinase may also highlight that there
is some underlying liver dysfunction in the presence of little or no heparin through the release
of so-called heparanoids, which are small heparin-like molecules like chondroitin sulfate that
may affect the TEG test and show an altered curve in the presence of heparinase [128–131]
Thromboelastography has been used by several authors to manage anticoagulation in ECMO
patients [58, 132–138]. The primary finding from these studies is that thromboelastography
detects platelet dysfunction and can help guide specific factor therapy. Only one study showed
that the thromboelastography results could actually predict bleeding [133]. The ultimate utility
of the test is to provide additional insight into the underlying coagulation cascade, and
pinpoint areas of concern when used in conjunction with the other coagulation tests [139, 140].
6.4. Prothrombin time (PT)
The prothrombin time is a laboratory test to assay the formation of a clot from the addition of
tissue factor, phospholipids, and calcium to patient plasma. The key difference between the
PT and the aPTT is the activating agent being tissue factor, which is believed to activate the
clotting cascade through the extrinsic pathway associated with cellular or tissue injury.
Although the traditional description of the clotting cascade being a waterfall cascade divided
into the separate intrinsic and extrinsic pathways that converge at the common pathway is no
longer technically valid, it is conceptually useful for teaching and some interpretation of
coagulation tests [141]. The PT test is very sensitive to particular reagents used because the
source of tissue factor and phospholipids was extraction from brain and other organs. As such,
it is necessary to normalize patient results in the face of changing lot numbers or manufacturers
by creating comparative assays on normal patients with no known liver dysfunction or oral
anticoagulant use (e.g., warfarin). The World Health Organization (WHO) provides an
international reference preparation of thromboplastin for calibration to create the international
sensitivity index (ISI) for a given preparation, and this is what is currently used in most facilities
[142]. For patients receiving heparin, the PT/INR is useful for determining the effects of disease
on the liver-independent of lower doses of heparin. Patients who are septic typically exhibit
an elevated INR due to derangement of the clotting cascade from multiple areas associated
with sepsis and/or liver dysfunction [143]. Thus, the goal INR for a patient on ECMO receiving
heparin therapy should be less than 1.5. For other anticoagulants, such the vitamin K antago‐
nists (e.g., warfarin), DTIs, or the newer oral Factor Xa inhibitors, the PT/INR would be
expected to be in the range of 2–3 or higher [144].
6.5. Anti-Xa assay
The anti-Xa assay is a chromogenic laboratory assay for determining the effective heparin
concentration in patient plasma. It is typically conducted by combining patient plasma
(containing UFH or LMWH) with an exogenous amount of factor Xa followed by a chromo‐
genic reaction for unbound factor Xa. Thus, more the color change, the less the heparin/AT
complex interacted with factor Xa, and therefore the lower the drug level. The test is highly
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sensitive to the relationship between heparin and AT; meaning that even with high levels of
UFH or LMWH, an AT deficiency will have more unbound factor Xa and read as a low heparin
level. Most importantly, this test does not measure thrombosis generation or the impact of
heparin (UFH or LMWH) or oral Xa inhibitors on the ultimate generation of thrombin [145].
While the test is valuable in helping clinicians achieve stable heparin drug levels and eliminate
inconsistency in the aPTT testing [146], patients on ECMO may have a complex underlying
derangement in the balance of their clotting factors. It is important to keep in mind that the
coagulation system is a series of enzymatic reactions, and having more substrate should
naturally require more inhibitor to control the balance. For example, an increased presence of
fibrinogen (i.e., hyperfibrinogenemia >500 mg/dL) or thrombin may tip the coagulation
cascade towards pro-thrombotic requiring additional anti-Xa levels (i.e., more heparin) to
modulate hemostasis. The expected range of anti-Xa levels on UFH therapy (0.3–0.8 IU/mL),
however, should be accompanied by further coagulation testing to determine the actual effect.
Xa levels of 0.3–0.8 IU/mL normally correlate with an aPTT of 90–110 seconds [147]. Because
the aPTT is dependent upon the reagents used, individual ranges must be established at each
institution in accordance with the College of American Pathologists’ recommendations [148].
Even within the same institution, individual patients on ECMO may have variations in their
underlying coagulation system or treatment that impacts the correlations between heparin
levels and their coagulation tests [126].
6.6. Anti-thrombin (AT)
The AT assay can be performed in a quantitative (immunologic) or qualitative (functional)
methodology, with the latter being preferred in most clinical labs because it can be done in a
simple chromogenic assay similar to the methodology for anti-Xa testing. In the qualitative
chromogenic assay, plasma is incubated with an excess amount of heparin in the presence of
FIIa (thrombin) followed by a chromogen for unbound FIIa. The values are reported as a
percentage of standard normal adult plasma (100%). Standard cut-off values for AT replace‐
ment while on heparin therapy are typically ≥ 60%. Replacement can be accomplished through
the use of fresh frozen plasma, which can raise AT levels approximately 20% for every
20ml/kg given. Alternatively, there are pharmacologic interventions using either pooled
human donor AT or a recombinant AT. Routine testing to drive the administration of AT on
ECMO has been performed at a number of centers and is gaining popularity despite a paucity
of safety and efficacy data [58].
6.7. D-dimer
The D-dimer protein is the cleaved product of the fibrinolysis process. The D-dimer test is
commercially available as an immunologic test for the specific D domain on cross-linked fibrin,
although available kits may not test for the exact same epitope. As such, the presence of D-
dimers in the blood indicates the formation of thrombin and subsequent conversion of
fibrinogen to fibrin and its polymerization to form a clot has previously occurred and is in the
process of resolving. D-dimer levels are typically elevated in patients who are experiencing
DIC because of sepsis, DVTs, pulmonary embolism, or other thrombotic disorders [149]. In the
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setting of ECMO, D-dimer may be a useful surrogate for the presence of thrombus in the
interior of the oxygenator and signal the need for circuit change due to consumptive coagul‐
opathy [150, 151].
ACT++  ACT-LR  aPTT  PT  TEG  Anti-Xa  AT  D-dimer 
Anticoagulant 
to be
monitored
Moderate-
high
heparin
dose (1-6
IU/mL)
Low-
moderate
heparin
dose (0-2.5
IU/mL)
Low
heparin
dose (0–1.5
IU/mL),
DTIs
Vitamin K 
inhibitors 
DTIs
Anti-Xa
agents
Low
heparin
dose
(0–1.5
IU/mL)
DTIs
Anti-
platelet
agents
UFH,
LMWH.,
oral anti-Xa
drugs
Substrate
availability 
for UFH
and
LMWH
Fibrinolysis
end
products
Used in CPB ECMO ECMO &
VAD
ECMO &
VAD
ECMO &
VAD
ECMO &
VAD
ECMO &
VAD
ECMO &
VAD
Test kit silica,
kaolin,
phospholipid 
Lower
conc.
silica,
kaolin,
phospholipid
Glass,
kaolin,
phospholipid 
Tissue
factor,
calcium
Kaolin
and Calcium;
Optional
heparinase
and platelet
agonists
for platelet
mapping
Excess
FXa
Colorimetric 
Assay
Chromo-genic
substrate
Latex
Agglutination
Blood
components
Tested
Whole
blood
Whole
Blood
Citrated
plasma
Citrated
Plasma
Citrated
whole
blood
Citrated
plasma
Citrated
Plasma
Citrated
Plasma
End
point
Clot
detection
Clot
Detection
Thrombus
detection
Thrombus
detection
Clot
Detection
and
breakdown
Bound
FXa
Available
AT
Available
Fibrin
split
products
The tests range in sensitivity to hemostatic factors from left (least sensitive) to right (most sensitive) Note that only the
ACT+, ACT-LR, aPTT, PT, and TEG measure coagulation as an endpoint.
Table 3. Table of the laboratory tests used for monitoring anticoagulation, their intended targets, test details, and
endpoints.
7. Conclusion
The history of anticoagulation and biocompatibility is a relatively short, but important part of
the development of mechanical circulatory assist devices. The use of surface coatings and
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systemic anticoagulation is at this point in clinical care considered a necessity for the successful
application of ECMO in the clinical setting. Although heparin continues to be the primary
anticoagulant of choice for patients on mechanical circulatory support, particularly ECMO,
the continued use of direct thrombin inhibitors may signal an end to the heparin era. The
philosophy adopted by the authors here is that it is important to start with a normal underlying
coagulation and inflammatory system prior to the introduction of systemic drugs designed to
alter the normal set point of this complex biological system. Furthermore, patients with altered
hemostatic systems may require “reset” or adjusted laboratory parameters in order to achieve
hemostasis. Many clinicians have often utilized plasmapheresis or plasma exchange to
accomplish this, although the use of these techniques expressly for the purpose of resetting
the hemostatic system in the ECMO setting is controversial and has not been adequately
studied or validated in a multi-center clinical trial. At best, it is considered to be a reasonably
safe adjuvant therapy to ECMO. Furthermore, the lack of a sufficient single coagulation test
to accurately assess the hemostatic status of an ECMO patient has resulted in the utilization
of a host of tests with the hopes that they agree and that we have achieved a safe, stable
anticoagulation profile. However, future efforts may obviate the need for a systemic anticoa‐
gulant by providing a surface or material that is truly biologically inert.
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